Dow Up0.26% Nasdaq Down1.07%

Transition Therapeutics Inc. (TTHI)

6.86 0.17(2.44%) Sep 15, 3:59PM EDT
ProfileGet Profile for:
Transition Therapeutics Inc.
101 College Street
Suite 220
Toronto, ON M5G 1L7
Canada - Map
Phone: 416-260-7770

Index Membership:N/A
Full Time Employees:16

Business Summary 

Transition Therapeutics Inc., a biopharmaceutical company, develops therapeutics for various disease indications primarily in Canada. Its lead CNS drug candidate includes ELND005, a Phase II clinical trial product for the treatment of Alzheimer's disease, bipolar disorder, and down syndrome; and lead metabolic drug candidate comprises TT-401 for the treatment of type 2 diabetes and accompanying obesity. The company’s product pipeline also consists of TT-402 to treat diabetes; and TT-601, a preclinical stage product for the treatment of osteoarthritis pain. It has strategic collaborations with Elan Pharma International Limited to develop and commercialize ELND005; and Eli Lilly and Company. The company was formerly known as Transition Therapeutics and Diagnostics Inc. and changed its name to Transition Therapeutics Inc. on December 2000. Transition Therapeutics Inc. was founded in 1987 and is headquartered in Toronto, Canada.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Transition Therapeutics Inc.

Key Executives 
Dr. Tony F. Cruz Ph.D., 61
Chairman and Chief Exec. Officer
Ms. Nicole Rusaw-George C.A, 41
Chief Financial Officer
Mr. Carl Damiani , 42
Chief Operating Officer
Dr. Aleksandra Pastrak , 48
VP of Clinical Devel. and Medical Officer
Dr. Bruce Connop Ph.D., 45
VP of Non-Clinical & Pharmaceutical Devel.
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders